Literature DB >> 32246201

[Immunoncology and tumor infiltrating lymphocytes-new strategies for therapy and diagnosis of breast cancer].

Carsten Denkert1.   

Abstract

Immunological parameters have been evaluated in breast cancer for many years in translational research projects. In the recent years, innovative therapy concepts have been developed from these research approaches, and very recently, first clinical trials have reported positive results. Based on these results there are now new options for combinations of immune checkpoint inhibitors and chemotherapy in breast cancer.

Entities:  

Keywords:  Breast cancer; Immune therapy; Translational research; Tumor immunology; Tumor-infiltrating lymphocytes

Year:  2020        PMID： 32246201     DOI： 10.1007/s00292-020-00783-y

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  19 in total

Review 1.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

2.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Authors:  Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

3.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Authors:  Carsten Denkert; Gunter von Minckwitz; Jan C Brase; Bruno V Sinn; Stephan Gade; Ralf Kronenwett; Berit M Pfitzner; Christoph Salat; Sherene Loi; Wolfgang D Schmitt; Christian Schem; Karin Fisch; Silvia Darb-Esfahani; Keyur Mehta; Christos Sotiriou; Stephan Wienert; Peter Klare; Fabrice André; Frederick Klauschen; Jens-Uwe Blohmer; Kristin Krappmann; Marcus Schmidt; Hans Tesch; Sherko Kümmel; Peter Sinn; Christian Jackisch; Manfred Dietel; Toralf Reimer; Michael Untch; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2014-12-22       Impact factor: 44.544

Review 4.  Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Authors:  Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

5.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

Authors:  Joseph McLaughlin; Gang Han; Kurt A Schalper; Daniel Carvajal-Hausdorf; Vasiliki Pelekanou; Jamaal Rehman; Vamsidhar Velcheti; Roy Herbst; Patricia LoRusso; David L Rimm
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

6.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

7.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Carsten Denkert; Sibylle Loibl; Aurelia Noske; Marc Roller; Berit Maria Müller; Martina Komor; Jan Budczies; Silvia Darb-Esfahani; Ralf Kronenwett; Claus Hanusch; Christian von Törne; Wilko Weichert; Knut Engels; Christine Solbach; Iris Schrader; Manfred Dietel; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Authors:  Mitch Dowsett; Torsten O Nielsen; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick; Matthew Ellis; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Christos Sotiriou; Ian E Smith; Giuseppe Viale; Jo Anne Zujewski; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2011-09-29       Impact factor: 13.506

9.  A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.

Authors:  S Loibl; M Untch; N Burchardi; J Huober; B V Sinn; J-U Blohmer; E-M Grischke; J Furlanetto; H Tesch; C Hanusch; K Engels; M Rezai; C Jackisch; W D Schmitt; G von Minckwitz; J Thomalla; S Kümmel; B Rautenberg; P A Fasching; K Weber; K Rhiem; C Denkert; A Schneeweiss
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

Review 10.  Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

Authors:  F Klauschen; K-R Müller; A Binder; M Bockmayr; M Hägele; P Seegerer; S Wienert; G Pruneri; S de Maria; S Badve; S Michiels; T O Nielsen; S Adams; P Savas; F Symmans; S Willis; T Gruosso; M Park; B Haibe-Kains; B Gallas; A M Thompson; I Cree; C Sotiriou; C Solinas; M Preusser; S M Hewitt; D Rimm; G Viale; S Loi; S Loibl; R Salgado; C Denkert
Journal:  Semin Cancer Biol       Date:  2018-07-07       Impact factor: 15.707
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.